Howard Bailey Securities LLC Acquires 198 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Howard Bailey Securities LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,094 shares of the company’s stock after purchasing an additional 198 shares during the quarter. Howard Bailey Securities LLC’s holdings in IDEXX Laboratories were worth $452,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. International Assets Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock valued at $2,669,890,000 after acquiring an additional 527,460 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in IDEXX Laboratories by 265.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after purchasing an additional 316,048 shares during the period. Seilern Investment Management Ltd purchased a new stake in IDEXX Laboratories in the fourth quarter worth approximately $113,104,000. Vontobel Holding Ltd. grew its position in IDEXX Laboratories by 3,325.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company’s stock worth $111,229,000 after purchasing an additional 213,731 shares during the period. Finally, Worldquant Millennium Advisors LLC raised its stake in IDEXX Laboratories by 230.1% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 110,196 shares of the company’s stock valued at $55,673,000 after buying an additional 76,809 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,330 shares of company stock valued at $6,161,276. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX opened at $457.35 on Thursday. The company has a 50 day simple moving average of $429.67 and a two-hundred day simple moving average of $453.23. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The firm has a market cap of $37.45 billion, a P/E ratio of 42.86, a PEG ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on IDXX shares. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley lowered their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Piper Sandler boosted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday. Finally, Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.